154 related articles for article (PubMed ID: 15380335)
1. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies.
Malek K; Boosalis MS; Waraska K; Mitchell BS; Wright DG
Leuk Res; 2004 Nov; 28(11):1125-36. PubMed ID: 15380335
[TBL] [Abstract][Full Text] [Related]
2. Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis.
Wright DG; Boosalis MS; Waraska K; Oshry LJ; Weintraub LR; Vosburgh E
Anticancer Res; 1996; 16(6A):3349-51. PubMed ID: 9042310
[TBL] [Abstract][Full Text] [Related]
3. Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
Tricot G; Weber G
Anticancer Res; 1996; 16(6A):3341-7. PubMed ID: 9042309
[TBL] [Abstract][Full Text] [Related]
4. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.
Wright DG; Boosalis M; Malek K; Waraska K
Leuk Res; 2004 Nov; 28(11):1137-43. PubMed ID: 15380336
[TBL] [Abstract][Full Text] [Related]
5. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
Tricot GJ; Jayaram HN; Lapis E; Natsumeda Y; Nichols CR; Kneebone P; Heerema N; Weber G; Hoffman R
Cancer Res; 1989 Jul; 49(13):3696-701. PubMed ID: 2567208
[TBL] [Abstract][Full Text] [Related]
6. Tiazofurin: biological effects and clinical uses.
Tricot G; Jayaram HN; Weber G; Hoffman R
Int J Cell Cloning; 1990 May; 8(3):161-70. PubMed ID: 2189014
[TBL] [Abstract][Full Text] [Related]
7. Sequential impact of tiazofurin and ribavirin on the enzymic program of the bone marrow.
Prajda N; Hata Y; Abonyi M; Singhal RL; Weber G
Cancer Res; 1993 Dec; 53(24):5982-6. PubMed ID: 7903199
[TBL] [Abstract][Full Text] [Related]
8. Hematological and biochemical action of tiazofurin (NSC 286193) in a case of refractory acute myeloid leukemia.
Tricot GJ; Jayaram HN; Nichols CR; Pennington K; Lapis E; Weber G; Hoffman R
Cancer Res; 1987 Sep; 47(18):4988-91. PubMed ID: 3476200
[TBL] [Abstract][Full Text] [Related]
9. Biochemical consequences of resistance to a recently discovered IMP dehydrogenase inhibitor, benzamide riboside, in human myelogenous leukemia K562 cells.
Jayaram HN; O'Connor A; Grant MR; Yang H; Grieco PA; Cooney DA
J Exp Ther Oncol; 1996 Sep; 1(5):278-85. PubMed ID: 9414415
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
11. Tiazofurin: molecular and clinical action.
Weber G; Prajda N; Abonyi M; Look KY; Tricot G
Anticancer Res; 1996; 16(6A):3313-22. PubMed ID: 9042306
[TBL] [Abstract][Full Text] [Related]
12. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Giles FJ; DeAngelo DJ; Baccarani M; Deininger M; Guilhot F; Hughes T; Mauro M; Radich J; Ottmann O; Cortes J
Semin Oncol; 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
[TBL] [Abstract][Full Text] [Related]
13. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
14. Recent development of IMP dehydrogenase inhibitors for the treatment of cancer.
Chen L; Pankiewicz KW
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):403-12. PubMed ID: 17659481
[TBL] [Abstract][Full Text] [Related]
15. p210 bcr-abl confers overexpression of inosine monophosphate dehydrogenase: an intrinsic pathway to drug resistance mediated by oncogene.
Gharehbaghi K; Burgess GS; Collart FR; Litz-Jackson S; Huberman E; Jayaram HN; Boswell HS
Leukemia; 1994 Aug; 8(8):1257-63. PubMed ID: 7520100
[TBL] [Abstract][Full Text] [Related]
16. Myeloperoxidase cytochemical negativity: an unexpected but intrinsic property of blasts of all phases of chronic myeloid leukemia.
Anand M; Ghara N; Kumar R; Singh S; Sengar M; Panikar N; Raina V; Sharma A
Ann Hematol; 2005 Nov; 84(12):767-70. PubMed ID: 15990995
[TBL] [Abstract][Full Text] [Related]
17. Enzyme-pattern-targeted chemotherapy with tiazofurin and allopurinol in human leukemia.
Weber G; Jayaram HN; Lapis E; Natsumeda Y; Yamada Y; Yamaji Y; Tricot GJ; Hoffman R
Adv Enzyme Regul; 1988; 27():405-33. PubMed ID: 2907968
[TBL] [Abstract][Full Text] [Related]
18. Tiazofurin down-regulates expression of c-Ki-ras oncogene in a leukemic patient.
Weber G; Nagai M; Natsumeda Y; Eble JN; Jayaram HN; Paulik E; Zhen WN; Hoffman R; Tricot G
Cancer Commun; 1991 Mar; 3(3):61-6. PubMed ID: 1705812
[TBL] [Abstract][Full Text] [Related]
19. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
[TBL] [Abstract][Full Text] [Related]
20. [Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].
Xing W; Gu BW; Zhu YM; Jiang CL; Zhao RH; Wang AH; Sun HP; Li JM; Shen ZX; Chen Z; Chen SJ
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):453-7. PubMed ID: 15854550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]